"ESC Guidelines: Integrating Latest Evidence-Based Treatments for Diabetes, Cardiovascular Disease, and Infective Endocarditis"

The European Society of Cardiology (ESC) has released new guidelines for managing cardiovascular disease (CVD) in patients with type 2 diabetes. The guidelines recommend starting treatment with both a sodium-glucose cotransporter-2 (SGLT-2) inhibitor and a glucagon-like peptide-1 (GLP-1) receptor agonist simultaneously, regardless of a person's existing level of glucose control. The guidelines also highlight the use of SGLT-2 inhibitors in people with heart failure and chronic kidney disease. Additionally, the ESC introduced a CVD risk calculator for people with type 2 diabetes without established CVD, heart failure, or CKD. The calculator estimates a person's 10-year risk for CVD and helps identify candidates for more aggressive treatment.